The features in the training set and internal validation set are ranked as follows: Clinical N staging, receipt of chemotherapy or radiotherapy, neural invasion, tumor histology, tumor length, number of peritumoral and total lymph nodes examined, liver metastasis, age, CEA, clinical T stage, and tumor length (Figure 4A). This evidence concerns the gene CEACAM5 and neoplasm.